Logo image of ARGX

ARGENX SE - ADR (ARGX) Stock Price, Quote, News and Overview

NASDAQ:ARGX - Nasdaq - US04016X1019 - ADR - Currency: USD

596.2  +8.61 (+1.47%)

After market: 596.2 0 (0%)

ARGX Quote, Performance and Key Statistics

ARGENX SE - ADR

NASDAQ:ARGX (4/17/2025, 8:02:23 PM)

After market: 596.2 0 (0%)

596.2

+8.61 (+1.47%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High678.21
52 Week Low352.77
Market Cap36.23B
Shares60.76M
Float60.68M
Yearly DividendN/A
Dividend YieldN/A
PE318.82
Fwd PE46.77
Earnings (Next)05-08 2025-05-08/bmo
IPO07-10 2014-07-10


ARGX short term performance overview.The bars show the price performance of ARGX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5

ARGX long term performance overview.The bars show the price performance of ARGX in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of ARGX is 596.2 USD. In the past month the price decreased by -2.75%. In the past year, price increased by 65.51%.

ARGENX SE - ADR / ARGX Daily stock chart

ARGX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.09 306.02B
AMGN AMGEN INC 13.99 149.08B
GILD GILEAD SCIENCES INC 22.68 130.32B
VRTX VERTEX PHARMACEUTICALS INC 1686.55 125.74B
REGN REGENERON PHARMACEUTICALS 12.34 61.56B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.51B
ONC BEIGENE LTD-ADR N/A 24.88B
BNTX BIONTECH SE-ADR N/A 23.74B
NTRA NATERA INC N/A 20.02B
SMMT SUMMIT THERAPEUTICS INC N/A 18.15B
BIIB BIOGEN INC 7.2 17.36B
INSM INSMED INC N/A 13.21B

About ARGX

Company Profile

ARGX logo image argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

Company Info

ARGENX SE - ADR

Laarderhoogtweg 25

Amsterdam NOORD-HOLLAND 4811 AH NL

CEO: Tim Van Hauwermeiren

Employees: 1148

Company Website: https://www.argenx.com/

Investor Relations: https://www.argenx.com/investors

Phone: 31763030

ARGENX SE - ADR / ARGX FAQ

What is the stock price of ARGENX SE - ADR today?

The current stock price of ARGX is 596.2 USD. The price increased by 1.47% in the last trading session.


What is the ticker symbol for ARGENX SE - ADR stock?

The exchange symbol of ARGENX SE - ADR is ARGX and it is listed on the Nasdaq exchange.


On which exchange is ARGX stock listed?

ARGX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ARGENX SE - ADR stock?

25 analysts have analysed ARGX and the average price target is 772.09 USD. This implies a price increase of 29.5% is expected in the next year compared to the current price of 596.2. Check the ARGENX SE - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARGENX SE - ADR worth?

ARGENX SE - ADR (ARGX) has a market capitalization of 36.23B USD. This makes ARGX a Large Cap stock.


How many employees does ARGENX SE - ADR have?

ARGENX SE - ADR (ARGX) currently has 1148 employees.


What are the support and resistance levels for ARGENX SE - ADR (ARGX) stock?

ARGENX SE - ADR (ARGX) has a support level at 555.1 and a resistance level at 602.18. Check the full technical report for a detailed analysis of ARGX support and resistance levels.


Is ARGENX SE - ADR (ARGX) expected to grow?

The Revenue of ARGENX SE - ADR (ARGX) is expected to grow by 60.95% in the next year. Check the estimates tab for more information on the ARGX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ARGENX SE - ADR (ARGX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARGENX SE - ADR (ARGX) stock pay dividends?

ARGX does not pay a dividend.


When does ARGENX SE - ADR (ARGX) report earnings?

ARGENX SE - ADR (ARGX) will report earnings on 2025-05-08, before the market open.


What is the Price/Earnings (PE) ratio of ARGENX SE - ADR (ARGX)?

The PE ratio for ARGENX SE - ADR (ARGX) is 318.82. This is based on the reported non-GAAP earnings per share of 1.87 and the current share price of 596.2 USD. Check the full fundamental report for a full analysis of the valuation metrics for ARGX.


What is the Short Interest ratio of ARGENX SE - ADR (ARGX) stock?

The outstanding short interest for ARGENX SE - ADR (ARGX) is 3.29% of its float. Check the ownership tab for more information on the ARGX short interest.


ARGX Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to ARGX. When comparing the yearly performance of all stocks, ARGX is one of the better performing stocks in the market, outperforming 94.24% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ARGX Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to ARGX. The financial health of ARGX is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARGX Financial Highlights

Over the last trailing twelve months ARGX reported a non-GAAP Earnings per Share(EPS) of 1.87. The EPS increased by 133.66% compared to the year before.


Industry RankSector Rank
PM (TTM) 38.03%
ROA 17.37%
ROE 19.54%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%155.36%
Sales Q2Q%82.18%
EPS 1Y (TTM)133.66%
Revenue 1Y (TTM)23.38%

ARGX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to ARGX. The Buy consensus is the average rating of analysts ratings from 25 analysts.

For the next year, analysts expect an EPS growth of 581.8% and a revenue growth 60.95% for ARGX


Ownership
Inst Owners39.35%
Ins Owners0.12%
Short Float %3.29%
Short Ratio6.99
Analysts
Analysts84
Price Target772.09 (29.5%)
EPS Next Y581.8%
Revenue Next Year60.95%